Drug intelligence / Profile preview

Alostop

Development stage: Preclinical
Lead developer: Reig Jofre Group
Modality: Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Alostop is a nanotechnology-based topical formulation developed by Reig Jofre Group for the treatment of alopecia. The therapy utilizes advanced nanotechnological delivery systems to optimize the penetration of active ingredients into the scalp and hair follicles. Currently in the preclinical stage, the project is part of Reig Jofre's innovation pipeline and aims to advance into exploratory clinical trials to provide a more effective solution for hair loss. The development is supported by national innovation projects in Spain and has been co-funded by the Centre for the Development of Industrial Technology (CDTI).

Brand names: Alostop
Other names: nanotechnological alopecia therapy

Beyond the preview

Go deeper on Alostop.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alostop.

Explore the full profile